Indication: This product is mainly suitable for respiratory system, urinary system, ENT, skin and soft tissue infections caused by sensitive bacteria.

Indication: It is mainly used for skin and soft tissue infections, biliary tract infections, respiratory tract infections, streptococcal pharyngitis, scarlet fever, diphtheria, Legionnaires' disease, whooping cough, etc. caused by sensitive Gram-positive bacteria, as well as gonorrhea, non-gonococcal urethritis, acne, etc.

Indication: It is mainly used for skin and soft tissue infections, biliary tract infections, respiratory tract infections, streptococcal pharyngitis, scarlet fever, diphtheria, Legionnaires' disease, whooping cough, etc. caused by sensitive Gram-positive bacteria, as well as gonorrhea, non-gonococcal urethritis, acne, etc.

Indication: It is mainly used for skin and soft tissue infections, biliary tract infections, respiratory tract infections, streptococcal pharyngitis, scarlet fever, diphtheria, Legionnaires' disease, whooping cough, etc. caused by sensitive Gram-positive bacteria, as well as gonorrhea, non-gonococcal urethritis, acne, etc.

Indication: This product is suitable for mild and moderate infections caused by penicillin-sensitive strains, including tonsillitis, pharyngitis, scarlet fever, erysipelas, etc. caused by streptococci; bronchitis, pneumonia, otitis media, sinusitis caused by pneumococci, and skin and soft tissue infections caused by sensitive staphylococci, etc. This product can also be used for spirochetal infections and as a preventive drug for recurrent rheumatic fever and infective endocarditis.

Indication: This product is suitable for mild and moderate infections caused by penicillin-sensitive strains, including tonsillitis, pharyngitis, scarlet fever, erysipelas, etc. caused by streptococci; bronchitis, pneumonia, otitis media, sinusitis caused by pneumococci, and skin and soft tissue infections caused by sensitive staphylococci, etc. This product can also be used for spirochetal infections and as a preventive drug for recurrent rheumatic fever and infective endocarditis.

Indication: Penicillin V potassium is suitable for mild and moderate infections caused by penicillin-sensitive strains, including tonsillitis, pharyngitis, scarlet fever, erysipelas, etc. caused by streptococci; bronchitis, pneumonia, otitis media, sinusitis caused by pneumococci; and skin and soft tissue infections caused by sensitive staphylococci, etc. Penicillin V potassium can also be used as a preventive drug for recurrent rheumatic fever and infective endocarditis, and can also be used for spirochetal infections.

Indication: To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infectionsen dash penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 alpha NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1

Indication: To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract. Staphylococcal infectionsen dash penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 alpha NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1

Indication: INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin G Procaine and other antibacterial drugs, Penicillin G Procaine should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin G procaine is indicated in the treatment of moderately severe infections in both adults and pediatric patients due to penicillin-G-susceptible microorganisms that are susceptible to the low and persistent serum levels common to this particular dosage form in the indications listed below. Therapy should be guided by bacteriological studies (including susceptibility tests) and by clinical response. NOTE: When high, sustained serum levels are required, aqueous penicillin G, either IM or IV, should be used. The following infections will usually respond to adequate dosages of intramuscular penicillin G procaine: Moderately severe to severe infections of the upper respiratory tract, skin and soft-tissue infections, scarlet fever, and erysipelas due to susceptible streptococci (Group A-without bacteremia) NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococcus), are resistant. Aqueous penicillin is recommended for streptococcal infections with bacteremia. Moderately severe infections of the respiratory tract due to susceptible pneumococci NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with aqueous penicillin G during the acute stage. Moderately severe infections of the skin and soft tissues due to susceptible staphylococci (penicillin G-susceptible NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Indicated surgical procedures should be performed. Fusospirochetosis (Vincent''s gingivitis and pharyngitis). Moderately severe infections of the oropharynx due to susceptible fusiform bacilli and spirochetes. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Syphilis (all stages) due to susceptible Treponema pallidum NOTE: This drug should not be used in the treatment of beta-lactamase producing organisms which include most strains of Neisseria gonorrhea Yaws, Bejel, Pinta due to susceptible organisms. Penicillin G procaine is an adjunct to antitoxin for prevention of the carrier stage of diphtheria due to susceptible C. diphtheriae Anthrax due to Bacillus anthracis Bacillus anthracis Rat-bite fever due to susceptible Streptobacillus moniliformis Spirillum minus Erysipeloid due to susceptible Erysipelothrix rhusiopathia Subacute bacterial endocarditis, only in extremely sensitive infections, due to susceptible Group A streptococci
Syphilis
Primary, secondary, and latent with a negative spinal fluid in adults and pediatric patients over 12 years of age: 600,000 units daily for 8 days-total 4,800,000 units. Late (tertiary, neurosyphilis, and latent syphilis with positive spinal-fluid examination or no spinal-fluid examination): 600,000 units daily for 10 to 15 days-total 6 to 9 million units. Congenital syphilis under 70-lb. body weight: 50,000 units/kg/day for 10 days. Yaws, Bejel, and Pinta: Treatment as for syphilis in corresponding stage of disease. Diphtheria-adjunctive therapy with antitoxin: 300,000 to 600,000 units daily. Diphtheria carrier state: 300,000 units daily for 10 days. Anthrax-cutaneous: 600,000 to 1,000,000 units/day. Anthrax-inhalational (post-exposure): 1,200,000 units every 12 hours in adults, 25,000 units per kilogram of body weight (maximum 1,200,000 unit) every 12 hours in children. The available safety data for penicillin G procaine at this dose would best support a duration of therapy of 2 weeks or less. Treatment for inhalational anthrax (post-exposure) must be continued for a total of 60 days. Physicians must consider the risks and benefits of continuing administration of penicillin G procaine for more than 2 weeks or switching to an effective alternative treatment. Vincent''s infection (fusospirochetosis): 600,000 to 1,000,000 units/day. Erysipeloid: 600,000 to 1,000,000 units/day. Streptobacillus moniliformis Spirillum minus Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.